Hydroquinone: An Evaluation of the Human Risks from its Carcinogenic and Mutagenic Properties

Abstract

The toxicology of hydroquinone has been reviewed on a number of previous occasions. This review targets its potential for carcinogenicity and possible modes of carcinogenic action. The evaluation made by IARC (1999) of its carcinogenic risk to humans was that hydroquinone is not classifiable as to its carcinogenicity to humans (Group 3). This evaluation was based on inadequate evidence in humans and limited evidence in experimental animals. The epidemiological information comes from four cohort studies involving occupational exposures. A cohort of lithographers, some of whom had worked with hydroquinone, had an excess of malignant melanoma based on five cases, but only two of the cases had reported exposure to hydroquinone. In a study of photographic processors the number of exposed individuals was uncertain and the numbers of cases of individual cancer sites were small. In view of the statistical power limitations of these studies for individual diagnostic categories of cancers, they are not considered to be informative with regard to the carcinogenicity of hydroquinone. A cohort of workers with definite and lengthy exposure to hydroquinone, during either its manufacture or its use, had low cancer rates compared with two comparison populations; the reason for the lower than expected rates is unclear. In a motion picture film processing cohort there were significant excess malignancies of the respiratory system among workers engaged in developing, where there was exposure to hydroquinone as well as other chemicals. There was no information on tobacco smoking habits and no dose-response relationship. Hydroquinone has been shown reproducibly to induce benign neoplasms in the kidneys of male F344 rats dosed orally either by gavage (25 and 50 mg/kg body weight) or diet (0.8%). The gavage study has been evaluated in considerable detail. This evaluation showed that all renal tubule adenomas and all cases of renal tubule atypical hyperplasia occurred in areas of severe or end-stage chronic progressive nephropathy and that the neoplasms were not otherwise confined to any particular part of the kidney. It is likely that the mode of carcinogenic action of hydroquinone is exacerbation of this natural disease process. Hydroquinone is mutagenic in vitro and in vivo, having caused genotoxicity or chromosomal aberrations in rodent bone-marrow cells. At least a portion, if not all, of the chromosomal effects are caused by interference by hydroquinone or its metabolites with chromosomal segregation, probably due to interaction with mitotic spindle proteins. However, the dose routes used to demonstrate these effects in almost all of the studies in vivo were intraperitoneal or subcutaneous injection, which were considered inappropriate. There were five studies by the oral route. These included a mouse bone-marrow cell micronucleus test in which a weak, marginally positive response was obtained following a single oral dose of 80 mg/kg body weight. The remaining oral route studies all showed no significant effect. They included a mou...

Phage Display–Mediated Discovery of Novel Tyrosinase-Targeting Tetrapeptide Inhibitors Reveals the Significance of N-Terminal Preference of Cysteine Residues and Their Functional Sulfur Atom

“…Known tyrosinase inhibitors, such as hydroquinone (Arndt and Fitzpatrick, 1965;Fitzpatrick et al, 1966), arbutin (Germanas et al, 2007), and kojic acid (Mishima et al, 1988;Elsner and Maibach, 2000;Ahn et al, 2011), are not completely adequately used in medicine and cosmetics today, because they are thought to be severely carcinogenic and can damage the structural architecture of several different tissues (Fujimoto et al, 1999;Philips et al, 2004;McGregor, 2007;Charlin et al, 2008). Meanwhile, peptides are thought to bind with exquisite specificity to their in vivo targets, resulting in exceptionally high potencies of action and relatively few offtarget side effects (Craik et al, 2013).…”

Accumulation of Mercury in Ovaries of Mice After the Application of Skin-lightening Creams

“…In addition to mercury, skin-lightening creams might contain other toxic ingredients such as steroids and hydroquinone. Though hydroquinone is allowed in the US by the FDA [66], it is banned in Europe because of its potential to cause cancer [67]. Only few people know about the dangers of these creams.…”

Cosmeceuticals in Dermatology

“…For this reason, its use has been restricted or highly regulated in some countries (Africa, Asia) [ 137 ] . Although carcinogenic effects, described in murine models, have not been proved in humans [ 139 ] , concern exists and it has caused the ban of hydroquinone containing products in Europe and Japan [ 137 ] .…”